Zobrazeno 1 - 10
of 746
pro vyhledávání: '"Luis, Puig"'
Autor:
Matthias Augustin, Alice B. Gottlieb, Mark Lebwohl, Andreas Pinter, Richard B. Warren, Luis Puig, Rhys Warham, Jérémy Lambert, Susanne Wiegratz, Balint Szilagyi, Andrew Blauvelt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2841-2857 (2024)
Abstract Introduction With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, par
Externí odkaz:
https://doaj.org/article/87932ef0b7d34aacbbdc912e39e468f6
Autor:
Luis Puig, Antonio Costanzo, Elke M. G. J. de Jong, Tiago Torres, Richard B. Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2539-2558 (2024)
Abstract Introduction The interleukin-23p19 subunit inhibitor, guselkumab, has demonstrated improvements in clinical and patient-reported outcome (PRO) measures in patients with moderate-to-severe psoriasis. Understanding the relationship among clini
Externí odkaz:
https://doaj.org/article/ab526a4a99574512a77a238ef4a81a03
Autor:
Alexander J. Stratigos, Marie A. Richard, Clio Dessinioti, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taieb, Myrto Trakatelli, Luis Puig, Thrasyvoulos Tzellos, Dimitrios Ioannides, for the EADV burden of skin diseases project team
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 2, Pp 591-599 (2024)
Abstract Background There is no population‐based evidence on the prevalence and impact of skin diseases in Greece. Objectives To describe the prevalence of 12 main skin diseases and their impact on quality of life (QoL) and feelings of stigmatizati
Externí odkaz:
https://doaj.org/article/0f344796a383446ebcefe1bb72a0350d
Autor:
Andreas Pinter, Ahmed M. Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Bang Truong, Luis Puig, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1259-1271 (2024)
Abstract Introduction Real-world data on the efficacy of risankizumab (RZB) in clinical moderate-to-severe plaque psoriasis (PsO) are limited. The RAPID study assessed real-world clinical and patient-reported outcomes in RZB-treated PsO patients usin
Externí odkaz:
https://doaj.org/article/6166294923574c7eb1b770f5d1d6b0c3
Autor:
Maria Teresa Fernandez-Figueras, Noelia Perez-Muñoz, Luis Puig, Rodolfo Posada-Caez, Rosa Ballester Victoria, Martha Henriquez, Eva Musulen
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Tumour budding (TB) correlates with increased local invasion in various neoplasms. Certain basal cell carcinomas (BCCs) exhibit local aggressiveness. Detecting adverse prognostic factors in partial biopsies could aid in identifying cases with heighte
Externí odkaz:
https://doaj.org/article/90972389062d448d9543e456c825cc9e
Autor:
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, Ryuta Sakuma, Luis Puig, Matthew Davis, Dominic Nunag, Andreas Pinter, Shinichi Imafuku
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 99-114 (2023)
Abstract Introduction Patients with moderate-to-severe psoriasis (PsO) treated with interleukin (IL)-inhibitors may require treatment modification to achieve disease control. This study evaluated discontinuation and switching of IL-inhibitors for PsO
Externí odkaz:
https://doaj.org/article/c7c766b9c1614705a27a88d773493cf3
Autor:
Giampiero Girolomoni, Laura Savage, Paolo Gisondi, Åke Svensson, Emmanuel Mahé, Matthias Augustin, Luis Puig
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 10, Pp 2171-2185 (2023)
Abstract Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psyc
Externí odkaz:
https://doaj.org/article/b18142dd5e224630bc28e18b5cd73f68
Autor:
Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkämper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1127-1146 (2023)
Abstract Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40–60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antib
Externí odkaz:
https://doaj.org/article/4c9392c1257a45e0b15c5bcafb3f3df9
Autor:
Alexander Egeberg, Lars Erik Kristensen, Luis Puig, Phoebe Rich, Saxon D. Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Available network meta-analyses (NMAs) comparing the efficacy of biologics in nail psoriasis (NP) have not included recently approved biologics such as bimekizumab nor have they provided comparisons up to 1 year. Objective We conducted two
Externí odkaz:
https://doaj.org/article/5362c29498f147efbcd364accd7a6767
Autor:
Victoria Navarro-Compán, Luis Puig, Silvia Vidal, Julio Ramírez, Mar Llamas-Velasco, Cristina Fernández-Carballido, Raquel Almodóvar, José Antonio Pinto, Eva Galíndez-Aguirregoikoa, Pedro Zarco, Beatriz Joven, Jordi Gratacós, Xavier Juanola, Ricardo Blanco, Salvador Arias-Santiago, Jesús Sanz Sanz, Rubén Queiro, Juan D. Cañete
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/b697cb4bed924dda8bb2f339178ead35